4.73
price down icon3.67%   -0.18
pre-market  Pre-market:  4.96   0.23   +4.86%
loading
Y Mabs Therapeutics Inc stock is traded at $4.73, with a volume of 197.46K. It is down -3.67% in the last 24 hours and down -23.34% over the past month. Y-mAbs Therapeutics Inc is a commercial-stage biopharmaceutical company. It is mainly engaged in the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer. DANYELZA, is the first FDA-approved product of the company which is a recombinant humanized immunoglobulin G, subtype 1k, or IgG1k, monoclonal antibody or mAb that targets ganglioside GD2, which is expressed in various neuroectoderm-derived tumors and sarcomas.
See More
Previous Close:
$4.91
Open:
$4.89
24h Volume:
197.46K
Relative Volume:
0.47
Market Cap:
$213.88M
Revenue:
$84.82M
Net Income/Loss:
$-21.43M
P/E Ratio:
-9.6531
EPS:
-0.49
Net Cash Flow:
$-27.23M
1W Performance:
-9.90%
1M Performance:
-23.34%
6M Performance:
-65.57%
1Y Performance:
-70.14%
1-Day Range:
Value
$4.695
$5.00
1-Week Range:
Value
$4.62
$5.28
52-Week Range:
Value
$4.57
$17.78

Y Mabs Therapeutics Inc Stock (YMAB) Company Profile

Name
Name
Y Mabs Therapeutics Inc
Name
Phone
646-885-8505
Name
Address
202 CARNEGIE CENTER, PRINCETON, NY
Name
Employee
107
Name
Twitter
Name
Next Earnings Date
2025-03-04
Name
Latest SEC Filings
Name
YMAB's Discussions on Twitter

Compare YMAB with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
Biotechnology icon
YMAB
Y Mabs Therapeutics Inc
4.73 213.88M 84.82M -21.43M -27.23M -0.49
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
502.92 129.14B 11.02B -535.60M -978.00M -2.20
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
680.61 74.41B 14.20B 4.41B 3.54B 38.28
Biotechnology icon
ARGX
Argen X Se Adr
581.21 35.31B 2.19B 833.04M -1.28B 12.71
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
241.75 31.30B 2.25B -278.16M -42.59M -2.17
Biotechnology icon
ONC
Beigene Ltd Adr
254.57 27.35B 3.32B -860.46M -1.04B -8.32

Y Mabs Therapeutics Inc Stock (YMAB) Upgrades & Downgrades

Date Action Analyst Rating Change
Nov-18-24 Initiated Oppenheimer Outperform
Aug-16-24 Initiated Cantor Fitzgerald Overweight
Jun-28-24 Initiated Truist Buy
May-10-23 Upgrade Wedbush Neutral → Outperform
Apr-03-23 Downgrade Guggenheim Buy → Neutral
Jan-27-23 Downgrade Morgan Stanley Equal-Weight → Underweight
Jan-05-23 Downgrade Cowen Outperform → Market Perform
Dec-02-22 Downgrade BofA Securities Buy → Neutral
Oct-31-22 Downgrade JP Morgan Neutral → Underweight
Oct-31-22 Downgrade Wedbush Outperform → Neutral
Jul-06-22 Resumed Canaccord Genuity Buy
Jun-24-22 Initiated BMO Capital Markets Outperform
Feb-03-22 Resumed Guggenheim Buy
Nov-19-21 Resumed Morgan Stanley Equal-Weight
Nov-16-21 Downgrade JP Morgan Overweight → Neutral
May-07-21 Upgrade BofA Securities Neutral → Buy
Apr-23-21 Resumed Cowen Outperform
Mar-22-21 Resumed JP Morgan Overweight
Jan-15-21 Downgrade BofA Securities Buy → Neutral
Nov-09-20 Reiterated H.C. Wainwright Buy
May-05-20 Initiated Barclays Overweight
May-01-20 Initiated Janney Buy
Apr-29-20 Initiated Morgan Stanley Equal-Weight
Dec-24-19 Initiated JP Morgan Overweight
Nov-20-19 Initiated Guggenheim Buy
Sep-04-19 Initiated Wedbush Outperform
Apr-01-19 Initiated H.C. Wainwright Buy
Oct-16-18 Initiated BTIG Research Buy
Oct-16-18 Initiated BofA/Merrill Buy
View All

Y Mabs Therapeutics Inc Stock (YMAB) Latest News

pulisher
Mar 13, 2025

12 Health Care Stocks Moving In Thursday's Pre-Market Session - Benzinga

Mar 13, 2025
pulisher
Mar 11, 2025

Y-mabs therapeutics CEO Michael Rossi sells $20,368 in stock - Investing.com

Mar 11, 2025
pulisher
Mar 11, 2025

Y-mabs therapeutics CBO Gad Thomas sells $56,536 in stock - Investing.com

Mar 11, 2025
pulisher
Mar 11, 2025

Y-mAbs Therapeutics Executives Sell Shares - TradingView

Mar 11, 2025
pulisher
Mar 11, 2025

Y-mAbs Therapeutics, Inc. (YMAB) Reports Q4 Loss, Lags Revenue Estimates - MSN

Mar 11, 2025
pulisher
Mar 11, 2025

YMAB Q1 EPS Estimate Boosted by Brookline Capital Management - MarketBeat

Mar 11, 2025
pulisher
Mar 09, 2025

Bearish: Analysts Just Cut Their Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Revenue and EPS estimates - Yahoo Finance UK

Mar 09, 2025
pulisher
Mar 08, 2025

FY2025 EPS Estimates for YMAB Reduced by Cantor Fitzgerald - Defense World

Mar 08, 2025
pulisher
Mar 08, 2025

Wedbush Reduces Earnings Estimates for Y-mAbs Therapeutics - Defense World

Mar 08, 2025
pulisher
Mar 07, 2025

From Clinical Trials to the Market: Cancer Stocks With Big Potential in 2025 - Baystreet.ca

Mar 07, 2025
pulisher
Mar 07, 2025

Y-mAbs Therapeutics, Inc. to Host Earnings Call - ACCESS Newswire

Mar 07, 2025
pulisher
Mar 07, 2025

Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Just Reported And Analysts Have Been Cutting Their Estimates - Simply Wall St

Mar 07, 2025
pulisher
Mar 07, 2025

Bank of America Lowers Y-mAbs Therapeutics (NASDAQ:YMAB) Price Target to $12.00 - Defense World

Mar 07, 2025
pulisher
Mar 07, 2025

Morgan Stanley Issues Pessimistic Forecast for Y-mAbs Therapeutics (NASDAQ:YMAB) Stock Price - Defense World

Mar 07, 2025
pulisher
Mar 07, 2025

Truist Financial Has Lowered Expectations for Y-mAbs Therapeutics (NASDAQ:YMAB) Stock Price - Defense World

Mar 07, 2025
pulisher
Mar 05, 2025

Forecasting The Future: 4 Analyst Projections For Y-mAbs Therapeutics - Benzinga

Mar 05, 2025
pulisher
Mar 05, 2025

Y-mAbs Therapeutics price target lowered to $12 from $14 at BofA - TipRanks

Mar 05, 2025
pulisher
Mar 05, 2025

Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Q4 2024 Earnings Call Transcript - Insider Monkey

Mar 05, 2025
pulisher
Mar 05, 2025

Truist Cuts Price Target on Y-mAbs Therapeutics to $18 From $21, Keeps Buy Rating -March 05, 2025 at 06:27 am EST - Marketscreener.com

Mar 05, 2025
pulisher
Mar 05, 2025

Y-mAbs Therapeutics Inc (YMAB) Q4 2024 Earnings Call Highlights: Strategic Realignment and ... By GuruFocus - Investing.com Canada

Mar 05, 2025
pulisher
Mar 04, 2025

Y-mAbs Therapeutics Reports 2024 Financial Results - TipRanks

Mar 04, 2025
pulisher
Mar 04, 2025

Y-mAbs Therapeutics’ Earnings Call Highlights Mixed Results - TipRanks

Mar 04, 2025
pulisher
Mar 04, 2025

Y-mAbs Therapeutics inks equity deal up to $35M - Investing.com India

Mar 04, 2025
pulisher
Mar 04, 2025

Y-mAbs Therapeutics Inc Enters Equity Distribution Agreement With Oppenheimer -March 04, 2025 at 04:32 pm EST - Marketscreener.com

Mar 04, 2025
pulisher
Mar 04, 2025

Y-mAbs Therapeutics inks equity deal up to $35M By Investing.com - Investing.com UK

Mar 04, 2025
pulisher
Mar 04, 2025

SEC Form 424B5 filed by Y-mAbs Therapeutics Inc. - Quantisnow

Mar 04, 2025
pulisher
Mar 04, 2025

Y-mAbs stock price target cut to $19 at Cantor Fitzgerald - Investing.com UK

Mar 04, 2025
pulisher
Mar 04, 2025

Wedbush Cuts Price Target on Y-mAbs Therapeutics to $21 From $23, Keeps Outperform Rating - Marketscreener.com

Mar 04, 2025
pulisher
Mar 04, 2025

Y-mAbs Therapeutics Inc reports results for the quarter ended December 31Earnings Summary - TradingView

Mar 04, 2025
pulisher
Mar 04, 2025

Y-mAbs Therapeutics (NASDAQ:YMAB) shareholders have endured a 79% loss from investing in the stock five years ago - Yahoo Finance

Mar 04, 2025
pulisher
Mar 04, 2025

Y-mAbs announces publication of Phase 2 interim results on naxitamab - Yahoo Finance

Mar 04, 2025
pulisher
Mar 04, 2025

Y-mAbs Therapeutics Reports Fourth Quarter 2024 Financial Results - TradingView

Mar 04, 2025
pulisher
Mar 04, 2025

Y-mAbs Reports Fourth Quarter 2024 Financial Results -March 04, 2025 at 07:06 am EST - Marketscreener.com

Mar 04, 2025
pulisher
Mar 04, 2025

Y-mAbs Reports Fourth Quarter 2024 Financial Results and Recent Corporate Developments - The Manila Times

Mar 04, 2025
pulisher
Mar 04, 2025

Y-mAbs Therapeutics reports Q4 EPS (15c), consensus (13c) - TipRanks

Mar 04, 2025
pulisher
Mar 04, 2025

Y-mAbs Therapeutics (NASDAQ:YMAB) Given “Outperform” Rating at Wedbush - Defense World

Mar 04, 2025
pulisher
Mar 03, 2025

Leptomeningeal Metastases Market Anticipated to Expand - openPR

Mar 03, 2025
pulisher
Mar 03, 2025

Naxitamab shows promise in neuroblastoma phase 2 trial - Investing.com

Mar 03, 2025
pulisher
Mar 03, 2025

Y-mAbs Announces Publication of Phase 2 Interim Results in Nature Communications - The Manila Times

Mar 03, 2025
pulisher
Mar 03, 2025

Y-mAbs Therapeutics Publishes Positive Interim Data on Naxitamab for High-Risk Neuroblastoma in Nature Communications - Nasdaq

Mar 03, 2025
pulisher
Mar 03, 2025

Can Y-mAbs' Neuroblastoma Therapy Turn 93% Survival Rate Into FDA Approval? - StockTitan

Mar 03, 2025
pulisher
Mar 03, 2025

How the (YMAB) price action is used to our Advantage - Stock Traders Daily

Mar 03, 2025
pulisher
Mar 03, 2025

YMAB CLASS ACTION: Hagens Berman, National Trial Attorneys, Encourages Y-mAbs Therapeutics (YMAB) Investors with Significant Losses to Contact Firm’s Attorneys, Securities Fraud Lawsuit Filed - ACCESS Newswire

Mar 03, 2025
pulisher
Mar 02, 2025

Y MABS THERAPEUTICS Earnings Preview: Recent $YMAB Insider Trading, Hedge Fund Activity, and More - Nasdaq

Mar 02, 2025
pulisher
Mar 02, 2025

Y-mAbs Therapeutics (YMAB) Expected to Announce Earnings on Tuesday - Defense World

Mar 02, 2025
pulisher
Mar 01, 2025

Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Receives Average Recommendation of “Buy” from Brokerages - Defense World

Mar 01, 2025
pulisher
Feb 27, 2025

Y-mAbs Therapeutics (YMAB) to Release Earnings on Tuesday - MarketBeat

Feb 27, 2025
pulisher
Feb 26, 2025

Shareholders in Y-mAbs Therapeutics (NASDAQ:YMAB) are in the red if they invested five years ago - Simply Wall St

Feb 26, 2025
pulisher
Feb 25, 2025

Y-mAbs Therapeutics, Inc. (YMAB) Expected to Beat Earnings Estimates: What to Know Ahead of Q4 Release - Yahoo Finance

Feb 25, 2025
pulisher
Feb 21, 2025

Y-mAbs to Announce Fourth Quarter and Full Year 2024 Financial and Operating Results on March 4, 2025 - Taiwan News

Feb 21, 2025
pulisher
Feb 20, 2025

Y-mAbs Therapeutics, Inc. to Announce Fourth Quarter and Full Year 2024 Results on March 4, 2025 - Nasdaq

Feb 20, 2025

Y Mabs Therapeutics Inc Stock (YMAB) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading
$75.07
price up icon 1.39%
$305.39
price down icon 0.55%
$19.19
price down icon 3.62%
$32.68
price down icon 0.52%
$97.47
price down icon 2.84%
biotechnology ONC
$254.57
price up icon 1.89%
Cap:     |  Volume (24h):